Search

everythinglearnresearchcommunity

for

Search:↓

The results of using Pyrilutamide, a hair loss treatment available on the gray market, and other treatments such as Minoxidil, Finasteride and RU58841.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

Hair loss discussion involves PRP (platelet rich plasma) treatment. PRP doesn't stop hair loss, only promotes regrowth; minoxidil is suggested as a better alternative.

Hair loss discussion involves pyrilutamide treatment. Slow regrowth observed, expecting 10 baby hairs on temple regions after 1 year.

Hair loss discussion includes PRP and exosomes treatments. Questioning effectiveness and ideal candidate for these treatments.

RU58841 has significantly improved the user's hair loss experience, alongside oral finasteride, dutasteride, 5 mg minoxidil, topical finasteride, dermastamping, and low-level laser therapy. The user is considering increasing their RU58841 dose from 75 mg to 100-150 mg daily.

The conversation discusses hair loss treatments, specifically Setipiprant, finasteride, and bimatoprost. Setipiprant is suggested for maintenance, while bimatoprost is for regrowth, and combining them with dermarolling is recommended for better results.

Male pattern baldness (MPB) may be influenced by androgen receptors in scalp hair follicles and potentially poor blood flow. Transplanted hair is not immune to DHT, and factors like inflammation and scalp tension might also contribute to hair loss.

The conversation is about hair loss treatments, specifically discussing RU58841, with concerns about its safety and lack of research. Alternatives like finasteride, dutasteride, and minoxidil are mentioned, with some users sharing personal experiences and side effects.

Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.

RU58841 stopped scalp itching for the user, providing relief from persistent itchiness associated with hair loss. Some users reported side effects like chest pain, while others found relief with different treatments like mometasone.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

The user is considering PRP with exosomes for hair loss after oral minoxidil and dutasteride failed to provide desired results. Despite suggestions for a hair transplant, the user is hesitant due to cost and complexity, and is unsure about other options.

Finasteride is effective for DHT/AR-driven hair loss but not for chromosome 20-driven cases, where treatments like minoxidil, prostaglandin analogs, and low-level laser therapy may be more beneficial. Genetic testing can help determine the underlying cause of hair loss to tailor treatment effectively.

RU58841 stopped shedding after two weeks and improved hair after eight months. Initial thinning may occur within the first month.

The conversation discusses the effectiveness and safety of hair loss treatments, specifically RU58841 and Pyrilutimide (Pyril), with users sharing that Pyril was no more effective than a placebo and expressing concerns about the safety of RU58841 based on personal experiences and the lack of pharmaceutical interest.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

OP is experiencing significant hair loss despite GFC and PRP treatments and has abnormal lab results. They are advised to consult a hair-focused dermatologist for further evaluation.

A dermatologist recommended PRP (Platelet Rich Plasma) and GFC (Growth Factor Concentrate) for pattern baldness, but online sources suggest they may not be effective. The user is seeking opinions on these treatments.

Dr. Tsuji and Riken announced a hair cloning cure with a 98.9% success rate, expected to be released in 10 years. Users expressed hope and skepticism about the affordability and timeline of the treatment.

RU58841 was the only treatment that slowed hair loss and reduced irritation for a DUPA sufferer after trying finasteride, minoxidil, and dutasteride with no success. The user continues using 6mg oral minoxidil, 0.5mg dutasteride, and an 8% RU58841 solution.

The user is using Minoxidil, Finasteride, Nizoral, Nutrafol supplements, and PRP sessions for hair loss treatment. They are concerned about the effectiveness of these treatments and whether they should continue or consider a hair transplant.

A 33-year-old female with androgenic alopecia experienced alopecia areata patches after PRP treatment. She is seeking others' experiences with PRP worsening alopecia areata.

First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hair follicles, potentially reducing side effects.

RU58841 is effective for long-term hair loss treatment, often used with finasteride or dutasteride for better results. Users report varying experiences with side effects and effectiveness, with some noting improvements and others experiencing shedding or needing to adjust dosages.

The conversation discusses the use of 5-alpha-reductase inhibitors like finasteride and dutasteride for hair loss in transgender women, particularly in relation to testosterone suppression. The original poster has been using dutasteride and is considering stopping it due to undetectable testosterone levels.

A non-binary individual experienced hair loss after stopping hormone replacement therapy and is using oral Dutasteride, oral Minoxidil, and ketoconazole shampoo. They are hopeful for regrowth but may use wigs due to the high cost and uncertain effectiveness of additional treatments like mesotherapy and PRP.

A user with frizzy transplanted hair is considering a keratin treatment after 10 months and is concerned about its safety and potential to accelerate hair loss or cause telogen effluvium. They are seeking advice on whether it is safe to proceed with the treatment.

A hair restoration case involved injecting four different doses of Verteporfin into the mid scalp and using Scalp MicroPigmentation (SMP) around the extraction areas. Photos were taken and an update will be shared soon.